These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8431019)

  • 21. The antimicrobial activity and beta-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents.
    Cheng AF; Ling TK; Lam AW; Fung KS; Wise R
    J Antimicrob Chemother; 1993 May; 31(5):699-709. PubMed ID: 8335498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-vitro and in-vivo antibacterial activity of LB10517, a novel catechol-substituted cephalosporin with a broad antibacterial spectrum.
    Song HK; Oh JI; Kim MY; Kim YZ; Kim IC; Kwak JH
    J Antimicrob Chemother; 1996 Apr; 37(4):711-26. PubMed ID: 8722537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
    Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo antibacterial activities of GV129606, a new broad-spectrum trinem.
    Di Modugno E; Broggio R; Erbetti I; Lowther J
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2742-8. PubMed ID: 9420050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and in vivo antibacterial activities of BO-1341, a new antipseudomonal cephalosporin.
    Nakagawa S; Sanada M; Matsuda K; Hashizume T; Asahi Y; Ushijima R; Ohtake N; Tanaka N
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1423-7. PubMed ID: 2510590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bactericidal activity of cefpirome (HR 810) against 513 gram-negative bacteria isolated from blood of septicemic patients.
    Bergeron MG; Bernier M
    Infection; 1994; 22(4):299-305. PubMed ID: 8002094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro antimicrobial activity of RU-59863, a C-7 catechol substituted cephalosporin.
    Erwin ME; Varnam D; Jones RN
    Diagn Microbiol Infect Dis; 1997 Jun; 28(2):93-100. PubMed ID: 9239501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CP6679, a new injectable cephalosporin with broad spectrum and potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
    Ida T; Tsushima M; Ishii T; Atsumi K; Tamura A
    J Infect Chemother; 2002 Jun; 8(2):138-44. PubMed ID: 12111566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of cefpirome against microorganisms isolated in haematology, oncology and intensive care units in Switzerland.
    Liassine N; Bille J; Breer C; Frei R; Wüst J; Auckenthaler R
    Scand J Infect Dis; 1997; 29(6):615-21. PubMed ID: 9571744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus.
    Hanaki H; Akagi H; Masaru Y; Otani T; Hyodo A; Hiramatsu K
    Antimicrob Agents Chemother; 1995 May; 39(5):1120-6. PubMed ID: 7625799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cefquinome (HR 111V). In vitro evaluation of a broad-spectrum cephalosporin indicated for infections in animals.
    Murphy SP; Erwin ME; Jones RN
    Diagn Microbiol Infect Dis; 1994 Sep; 20(1):49-55. PubMed ID: 7867299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2003 Oct; 56(5):437-57. PubMed ID: 14692380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo activities of a new quinolone, WIN 57273, possessing potent activity against gram-positive bacteria.
    Sedlock DM; Dobson RA; Deuel DM; Lesher GY; Rake JB
    Antimicrob Agents Chemother; 1990 Apr; 34(4):568-75. PubMed ID: 2344163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1995). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Takanashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Kosakai N; Yamaguchi K; Matsumoto T; Kashitani F; Tanaka M
    Jpn J Antibiot; 1997 Mar; 50(3):219-50. PubMed ID: 9575353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin compared with other parenteral cephems.
    Jones RN; Erwin ME; Barrett MS; Johnson DM; Briggs BM
    Diagn Microbiol Infect Dis; 1991; 14(4):301-9. PubMed ID: 1889181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-susceptible and -resistant and tolerant and nontolerant Staphylococcus aureus.
    Goldstein EJ; Citron DM
    Antimicrob Agents Chemother; 1985 Jul; 28(1):160-2. PubMed ID: 3929677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
    Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo evaluation of Ro 09-1428, a new parenteral cephalosporin with high antipseudomonal activity.
    Arisawa M; Sekine Y; Shimizu S; Takano H; Angehrn P; Then RL
    Antimicrob Agents Chemother; 1991 Apr; 35(4):653-9. PubMed ID: 1906261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vitro and in-vivo antibacterial activities of E1040, a new cephalosporin with potent antipseudomonal activity.
    Hiruma R; Otsuki M; Tashima M; Obana Y; Nishino T
    J Antimicrob Chemother; 1990 Dec; 26(6):769-81. PubMed ID: 2127928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
    Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.